新冠病毒蛋白相互作用圖譜揭示藥物再利用的靶點
作者:
小柯機器人發布時間:2020/5/2 13:19:33
美國加州大學舊金山分校Nevan J. Krogan、Brian K. Shoichet、Kevan M. Shokat、西奈山伊坎醫學院Adolfo García-Sastre、法國巴斯德研究所Marco Vignuzzi等研究人員,合作繪製了SARS-CoV-2蛋白質相互作用圖譜,從而揭示了藥物再利用的靶點。該研究於2020年4月30日在線發表於《自然》。
研究人員表示,新冠病毒SARS-CoV-2是COVID-19呼吸系統疾病的病原體,在全世界範圍內造成了社會和經濟破壞。目前,尚無具有經臨床驗證的抗病毒藥物,也沒有用於預防的疫苗,而且對SARS-CoV-2感染的分子細節了解有限。
為了解決這個問題,研究人員在人類細胞中克隆、標記和表達了29種SARS-CoV-2蛋白中的26種,並使用親和純化質譜(AP-MS)鑑定了與每種蛋白物理相關的人類蛋白,從而確定了332種高可信度SARS -CoV-2-人蛋白-蛋白相互作用(PPI)。
其中,研究人員確定了69種化合物(29種FDA批准的藥物、12種臨床試驗的藥物以及28種臨床前化合物)靶向的66種可成藥的人類蛋白質或宿主因子。在多個病毒測定中篩選這些子集,研究人員確定了兩類具有抗病毒活性的藥理製劑:mRNA翻譯抑制劑和Sigma1和Sigma2受體的預測調節因子。
對這些宿主因子靶向劑的進一步研究,包括與直接靶向病毒酶的藥物聯合使用,可能會產生COVID-19的治療方案。
附:英文原文
Title: A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Author: David E. Gordon, Gwendolyn M. Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Kris M. White, Matthew J. OMeara, Veronica V. Rezelj, Jeffrey Z. Guo, Danielle L. Swaney, Tia A. Tummino, Ruth Huettenhain, Robyn M. Kaake, Alicia L. Richards, Beril Tutuncuoglu, Helene Foussard, Jyoti Batra, Kelsey Haas, Maya Modak, Minkyu Kim, Paige Haas, Benjamin J. Polacco, Hannes Braberg, Jacqueline M. Fabius, Manon Eckhardt, Margaret Soucheray, Melanie J. Bennett, Merve Cakir, Michael J. McGregor, Qiongyu Li, Bjoern Meyer, Ferdinand Roesch, Thomas Vallet, Alice Mac Kain, Lisa Miorin
Issue&Volume: 2020-04-30
Abstract: The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 2.3 million people, killed over 160,000, and caused worldwide social and economic disruption1,2. There are currently no antiviral drugs with proven clinical efficacy, nor are there vaccines for its prevention, and these efforts are hampered by limited knowledge of the molecular details of SARS-CoV-2 infection. To address this, we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), identifying 332 high-confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Screening a subset of these in multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further studies of these host factor targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.
DOI: 10.1038/s41586-020-2286-9
Source: https://www.nature.com/articles/s41586-020-2286-9